IndustryCompany release

Acrivon acquires Aqilion's oral JAK1 inhibitor ACR-525 and PKCθ programme, entering immunology

🇺🇸 Acrivon Therapeutics, Inc. (ACRV) · Fri 06 Nov 2026

The US oncology-focused biotech has bought a Phase 2-ready selective JAK1 inhibitor and a preclinical PKCθ programme for undisclosed cash, with no future royalties or milestones owed to Aqilion.

Acrivon Therapeutics announced on 6 November 2026 that it has acquired ACR-525, an oral, selective JAK1 inhibitor previously known as AQ280, from Aqilion AB. The deal also covers a preclinical programme targeting PKCθ. The company describes the move as its entry into immunology.

Acrivon did not disclose the cash price. It said the transaction carries no future royalties or milestone payments to Aqilion.

Eosinophilic esophagitis is the first indication Acrivon intends to pursue with ACR-525. The company sees inflammatory bowel disease as a longer-term opportunity for the asset.

Acrivon also reached a separate agreement that ends earlier royalty and milestone obligations to LEO Pharma. Together with the Aqilion terms, this leaves the programme without disclosed downstream payment liabilities to either party.

The company has scheduled a key opinion leader (KOL) webcast for 10 November 2026. The source material available did not give further detail on clinical plans, timelines or the financial terms of the LEO Pharma agreement.

What it means for your team

  • Market-access teams should note that ACR-525 is positioned first in eosinophilic esophagitis, a setting where any future launch would be assessed against existing treatment options.
  • Regulatory teams tracking JAK inhibitors should watch for Acrivon's development plan, as the company has not yet set out trial design or filing timelines.
  • The clearing of royalty and milestone obligations to Aqilion and LEO Pharma simplifies the asset's ownership position, though the financial terms remain undisclosed.
  • The 10 November KOL webcast is the next likely source of detail on clinical strategy.

Company's press release (SEC filing): Acrivon Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Acrivon Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →